You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

  • Authors: Steven E. Nissen, MD; Christie M. Ballantyne, MD; Stephen J. Nicholls, MBBS, PhD, FRACP
  • CME Released: 6/6/2013
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/6/2014
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, lipid specialists, endocrinologists, primary care physicians, and other physicians involved in the care of patients with hypercholesterolemia.

The goal of this activity is to provide focused education and practical guidance on the evidence-based use of intensive low-density lipoprotein cholesterol (LDL-C) reduction to manage residual cardiovascular risk within the limitations of current lipid-modifying therapy.

Upon completion of this activity, participants will be able to:

  1. Summarize the need for additional LDL-C reduction in patients with residual cardiovascular risk despite current lipid-modifying therapy
  2. Describe the mechanism of action of proprotein convertase subtilisin/kexin 9 (PCSK9) in regulation of cholesterol homeostasis
  3. Review efficacy and safety data for the various PCSK9 inhibitors


Disclosures

Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.


Author(s)

  • Steven E. Nissen, MD

    Co-Activity Director; Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Chairman, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio

    Disclosures

    Disclosure: Steven E. Nissen, MD, has disclosed no relevant financial relationships.

  • Christie M. Ballantyne, MD

    Professor of Medicine, Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart & Vascular Center, Baylor College of Medicine, Houston, Texas

    Disclosures

    Disclosure: Christie M. Ballantyne, MD, has disclosed the following relevant financial relationships:
    Consultant: Abbott Laboratories; Aegerion Pharmaceuticals, Inc.; Amarin Corporation plc; Amgen Inc.; Arena Pharmaceticals, Inc.; Cerenis Therapeutics; Esperion Therapeutics, Inc.; Genentech, Inc.; Genzyme Corporation; Kowa Company Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals, Inc.; Omthera Pharmaceuticals, Inc.; , Pfizer Inc; Resverlogix Corp; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi-Synthelabo
    Speakers Bureau: Abbott Laboratories; GlaxoSmithKline
    Grant/Research Support (All paid to institution, not individual): Abbott Laboratories; Amarin Corporation plc; Amgen Inc.; Lilly USA, LLC; GlaxoSmithKline; Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi-Synthelabo; Takeda Pharmaceuticals North America, Inc.; NIH; AHA

  • Stephen J. Nicholls, MBBS, PhD, FRACP

    Professor of Cardiology, SAHMRI Heart Foundation Heart Disease Theme Leader, South Australian Health & Medical Research Institute, Adelaide, Australia

    Disclosures

    Disclosure: Stephen J. Nicholls, MBBS, PhD, FRACP, has disclosed the following relevant financial relationships:
    Independent Contractor (including contracted research): Amgen Inc.; Takeda Pharmaceuticals North America, Inc.; AstraZeneca Pharmaceuticals LP; Roche, Eli Lilly and Company; Resverlogix Corp.
    Served as an advisor or consultant for: Amgen Inc.; Takeda Pharmaceuticals North America, Inc.; AstraZeneca Pharmaceuticals LP; Roche, Eli Lilly and Company; Resverlogix Corp, Merck

Editor(s)

  • Ronald K. Miller, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

  • Javier F. Negrón, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Javier F. Negrón, PhD, has disclosed no relevant financial relationships.

Activity Co-Director

  • Katherine J. Hoercher, RN

    Co-Activity Director; Senior Director, Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio

    Disclosures

    Disclosure: Katherine J. Hoercher, RN, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Content reviewers have no relevant financial relationships to disclose.


Accreditation Statements

    For Physicians

  • The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

Authors: Steven E. Nissen, MD; Christie M. Ballantyne, MD; Stephen J. Nicholls, MBBS, PhD, FRACPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 6/6/2013

Valid for credit through: 6/6/2014

processing....

This feature requires the newest version of Flash. You can download it here.
  • Print